Polynucleotide (e.g., Nucleic Acid, Oligonucleotide, Etc.) Patents (Class 435/91.1)
  • Patent number: 10738306
    Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5?UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3?UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: August 11, 2020
    Assignee: CureVac AG
    Inventor: Andreas Thess
  • Patent number: 10704084
    Abstract: The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 7, 2020
    Assignee: TriBiotica LLC
    Inventors: Ian Dunn, Matthew Lawler
  • Patent number: 10688174
    Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: June 23, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
  • Patent number: 10639609
    Abstract: De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 5, 2020
    Assignee: TWIST BIOSCIENCE CORPORATION
    Inventors: William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle
  • Patent number: 10618024
    Abstract: De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: April 14, 2020
    Assignee: TWIST BIOSCIENCE CORPORATION
    Inventors: William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle
  • Patent number: 10576446
    Abstract: Provided herein is a method for capturing DNA molecules in solution. The method may comprise: extracting DNA from a sample that comprises endogenous DNA and environmental DNA to produce extracted DNA; ligating universal adaptors to the extracted DNA; hybridizing the extracted DNA, in solution, with affinity-tagged RNA probes generated by: in vitro transcribing a library of fragmented reference genomic DNA that has been ligated to an RNA promoter adaptor, in the presence of an affinity-tagged ribonucleotide; binding the product with a capture agent that is tethered to a substrate in the presence of RNA oligonucleotides that are complementary to the adaptors, thereby capturing the hybridized DNA molecules on the substrate; washing the substrate to remove any unbound DNA molecules; and releasing the captured DNA molecules. A kit for performing the method is also provided.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: March 3, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Carlos D. Bustamante, Meredith L. Carpenter, Jason D. Buenrostro, William J. Greenleaf
  • Patent number: 10564118
    Abstract: Methods for detecting polynucleotides, especially the DNA replicated from samples obtained from subjects infected with pathogenic viruses such as human immunodeficiency virus, by detecting electromagnetic signals (“EMS”) emitted by such polynucleotides, and methods for improving the sensitivity of the polymerase chain reaction (“PCR”).
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 18, 2020
    Inventor: Luc Montagnier
  • Patent number: 10538795
    Abstract: The present invention relates to methods for generating a labelled nucleic acid from an RNA comprising a 5? protecting group, said method comprises the steps of obtaining a mixture of template strands of nucleic acids, said mixture comprising said RNA and further potentially other nucleic acids without a 5? protecting group, annealing at least one oligonucleotide primer to the template strand of said RNA and potentially other nucleic acids, and template sequence dependent extending said primer, thereby obtaining a complementary nucleic acid strand annealed to its template strand, or providing the RNA in duplex with a complementary nucleic acid strand annealed to its template strand, and optionally modifying the extension product of said nucleic acids without 5? protecting group either on the 5? end of the template strand or on the 3? end of the complementary strand, or both, and labelling a complementary nucleic acid of a double stranded nucleic acid not modified, wherein therefore the labelled nucleic acid d
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: January 21, 2020
    Assignee: LEXOGEN GMBH
    Inventors: Alexander Seitz, Irmlind Gabler, Lukas Paul
  • Patent number: 10538762
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Provided herein are a double-stranded oligonucleotides of 13 to 22 nucleobases in length targeting a GGGGCC expanded repeat region in an intron of C9orf72, comprises (a) 3-5 central mismatches (within bases 9-14) within a target sequence comprising the expanded repeat sequence, or (h) 3-5 mismatches outside of the seed sequence (bases 2-8 within the guide strand complementary to the expanded repeat sequence).
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 21, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David Corey, Jiaxin Hu
  • Patent number: 10519498
    Abstract: The invention relates to methods, compositions, devices, systems and kits are described including, without limitation, reagents and mixtures, for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: December 31, 2019
    Assignee: Qiagen Sciences, LLC
    Inventor: James J. DiMeo
  • Patent number: 10487353
    Abstract: Reaction mixture containing an analyte probe and an internal control probe, where the analyte probe and the internal control probe target different nucleic acids and have labels that generate signals that are indistinguishable from each other.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 26, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Sunghae A. Joo, Janel M. Dockter
  • Patent number: 10465184
    Abstract: The present invention relates to a method for preparing highly active silica magnetic nanoparticles, highly active silica magnetic nanoparticles prepared by the method, and a method of isolating nucleic acid using the highly active silica magnetic nanoparticles. The highly active silica magnetic nanoparticles prepared according to the present invention contain magnetic nanoparticles completely coated with silica, can be used as a reagent for isolating biomaterials, particularly, nucleic acids, and can isolate and purify nucleic acid in a high yield.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: November 5, 2019
    Assignee: BIONEER CORPORATION
    Inventors: Han Oh Park, Jae Ha Kim, Jong Gwang Park
  • Patent number: 10450595
    Abstract: Methods and compositions for the amplification of nucleic acids and generation of concatemers are disclosed. Amplification methods provided herein may be performed under isothermal conditions. Methods and compositions may include reagents such as nucleic acid polymerases and primers.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: October 22, 2019
    Assignee: Theranos IP Company, LLC
    Inventors: Kamila Belhocine, Josephine Lee, Pranav Patel, Aaron Richardson, Scott Tabakman
  • Patent number: 10421990
    Abstract: A method and kits are provided for nucleic acid quantification and discrimination using surface plasmon resonance (SPR). The method provided is able to significantly enhance the detection limit and multiplex the discrimination assay using the melting properties of the target DNA on top of standard PCR reaction. By using the heating and cooling cycles of the polymerase chain reaction (PCR) or Ligation chain reaction (LCR), DNA is melted and hybridized onto the SPR sensor surface together with a nanoparticle label. Thus, during every cycle of DNA amplification, the quantity and type of target DNA can be monitored.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: September 24, 2019
    Assignee: FOX BIOSYSTEMS NV
    Inventors: Jeroen Lammertyn, Karel Knez, Filip Delport
  • Patent number: 10385393
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: August 20, 2019
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 10344282
    Abstract: The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene. Certain such compounds are useful for hybridizing to a portion of the IKBKAP gene, including but not limited to a portion of the IKBKAP gene in a cell. In certain embodiments, such hybridization results in modulation of splicing of the IKBKAP gene. In certain embodiments, the IKBKAP gene includes a mutation that results in defective splicing and a truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in a decrease in the amount of defective splicing and truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in an increase in the amount of normal splicing and functional, full-length IKAP protein. In certain embodiments, oligonucleotides are used to treat Familial Dysautonomia.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: July 9, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., COLD SPRING HARBOR LABORATORY
    Inventors: C. Frank Bennett, Frank Rigo, Adrian R. Krainer, Rahul Sinha
  • Patent number: 10323078
    Abstract: A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 18, 2019
    Assignees: Universite Paris Descartes, Assistance Publique—Hopitaux De Paris, Universite Paris—Sud, Universite Pierre et Marie Curie (Paris 6), Institut National De La Sante et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Institut Gustave-Roussy
    Inventors: Nicolas Dupin, Philippe Grange, Vincent Calvez, Joël Raingeaud
  • Patent number: 10307469
    Abstract: Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 4, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Charles P. Venditti, Randy J. Chandler
  • Patent number: 10308944
    Abstract: The present invention relates to polypeptide expression systems and methods of using the same.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 4, 2019
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Yonglei Shang
  • Patent number: 10214573
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include Amyotrophic Lateral Sclerosis (ALS), as well as muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: February 26, 2019
    Assignees: Tivorsan Pharmaceuticals, Inc., Brown University
    Inventors: Justin Fallon, Elizabeth John
  • Patent number: 10202642
    Abstract: Provided herein is technology relating to sequencing nucleic acids and particularly, but not exclusively, to methods, compositions, systems, and kits for sequencing a nucleic acid using a degenerate two-base code. Particular embodiments provide: 1) that the two-base degenerate code relates a first element to a base comprising adenine (A) or guanine (G) and a second element to a base comprising cytosine (C) or thymine (T); 2) that the two-base degenerate code relates a first element to a base comprising A or C and a second element to a base comprising G or T; and 3) that the two-base degenerate code relates a first element to a base comprising G or C and a second element to a base comprising A or T.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: February 12, 2019
    Assignee: IBIS BIOSCIENCES, INC.
    Inventor: Mark W. Eshoo
  • Patent number: 10167508
    Abstract: The present invention provides assay systems and related methods for determining genetic abnormalities in mixed samples comprising cell free DNA from both normal and putative genetically atypical cells. Exemplary mixed samples for analysis using the assay systems of the invention include samples comprising both maternal and fetal cell free DNA and samples that contain DNA from normal cells and circulating cancerous cells.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: January 1, 2019
    Assignee: ARIOSA DIAGNOSTICS, INC.
    Inventors: Ken Song, Arnold Oliphant, John Stuelpnagel, Andrew Sparks
  • Patent number: 10087465
    Abstract: Compounds of the formula (Z)x wherein: each Z is independently selected from 2?-deoxythymidinyl moiety, 2?-deoxyadenosinyl moiety, and a 2?-deoxycytidinyl moiety, x is an integer from 5-20, wherein said 2?-deoxythymidinyl moieties are connected by thiophosphate triester linkages, and 3-12 of said thiophosphate triester linkages being positively charged linkages of the formula: where n is an integer from 2 to 6; and the remainder of the thiophosphate triester linkages are neutral linkages of the formula: provided that when x is 5-6, the number of positively charged linkages is 3, when x is 7-8, the number of positively charged linkages is 3-4, when x is 9-12, the number of positively charged linkages is 3-10, and when x is 13-20, the number of positively charged linkages is 4-12.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: October 2, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Serge L. Beaucage, Harsh V. Jain
  • Patent number: 10081837
    Abstract: In some embodiments, methods for obtaining sequence information from a nucleic acid template linked to a support include hybridizing a first primer to a template strand linked to a support, sequencing a portion of the nucleic acid template, thereby forming an extended first primer product that is complementary to a portion of the nucleic acid template, In some embodiments, the method further includes introducing a nick into a portion of the template strand that is hybridized to the extended first primer product, degrading a portion of the template strand from the nick using a degrading agent, where a portion of the extended first primer remains hybridized to an undegraded portion of the template strand, and sequencing at least some of the single-stranded portion of the extended first primer by synthesis.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: September 25, 2018
    Assignee: Life Technologies Corporation
    Inventors: Jason Myers, Zhoutao Chen, Devin Dressman, Theo Nikiforov
  • Patent number: 10083341
    Abstract: Methods and systems for quantifying cellular activity using labeled probes, e.g., quantum dots, are disclosed. In one example approach, a method for quantifying cellular activity in a sample containing intact cells having labeled complexes comprises receiving images of the sample at a plurality of depths and detecting individual intact cells in the images of the sample at the plurality of depths. For each detected cell, discrete labels may be detected and localized in the cell at each depth, a total number of detected and localized labels may be calculated in the cell, and an activity level of the target molecule for the labeled probe in the cell determined.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: September 25, 2018
    Assignee: Oregon Health & Science University
    Inventors: Tania Vu, Thomas Jacob
  • Patent number: 10041060
    Abstract: Methods are provided for constructing a synthetic genome, comprising generating and assembling nucleic acid cassettes comprising portions of the genome, wherein at least one of the nucleic acid cassettes is constructed from nucleic acid components that have been chemically synthesized, or from copies of the chemically synthesized nucleic acid components. In one embodiment, the entire synthetic genome is constructed from nucleic acid components that have been chemically synthesized, or from copies of the chemically synthesized nucleic acid components. Rational methods may be used to design the synthetic genome (e.g., to establish a minimal genome and/or to optimize the function of genes within a genome, such as by mutating or rearranging the order of the genes). Synthetic genomes of the invention may be introduced into vesicles (e.g., bacterial cells from which part or all of the resident genome has been removed, or synthetic vesicles) to generate synthetic cells.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: August 7, 2018
    Assignee: Synthetic Genomics, Inc.
    Inventors: J. Craig Venter, Hamilton O. Smith, Clyde A. Hutchison, III, Daniel G. Gibson
  • Patent number: 10030267
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: July 24, 2018
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 9951386
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: April 24, 2018
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 9951333
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 24, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Charlotte Albaek Thrue, Majken Westergaard, Christoph Rosenbohm
  • Patent number: 9950001
    Abstract: The disclosure provides methods and compositions for delivering polynucleotides into cells. The disclosure provides transiently protected polynucleotides comprising an anionic charge-neutralizing moiety/group, which may also confer additional functionality. These compounds can enter the cytosol of cells by endocytic or macropinocytic mechanisms. The transient protecting group is bioreversible, i.e., once inside a cell, it is designed to be removed by enzymatic activity or by passive intracellular methods (e.g., changes in pH or reductive environment).
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: April 24, 2018
    Assignee: The Regents of the University of California
    Inventors: Steven F. Dowdy, Bryan R. Meade, Khirud Gogoi
  • Patent number: 9920305
    Abstract: Compositions and methods are provided for improved reverse transcriptases and their uses in reverse transcription where the improvement may include increased temperature, increased salt, increased activity and/or increased dUTP tolerance.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: March 20, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Yinhua Zhang, Thomas C. Evans, Jr.
  • Patent number: 9884885
    Abstract: This invention relates to novel method of synthesis of RNA utilizing N-2-acetyl protected guanine as nucleoside base, nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N-acetyl protected guanine as nucleoside base protecting group, which is significantly faster base labile protecting group, yet significantly more stable than commonly utilized-2-isobutyryl guanosine is a novel approach to obtain highest purity oligonucleotides. This approach is designed to lead to very high purity and very clean oligonucleotide, after efficient removal of the protecting groups, including acetyl group from guanine and to produce high purity therapeutic grade DNA oligonucleotides, RNA oligonucleotides, diagnostic DNA, diagnostic RNA for microarray platform.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: February 6, 2018
    Assignee: CHEMGENES CORPORATION
    Inventors: Suresh C. Srivastava, Naveen P. Srivastava
  • Patent number: 9862998
    Abstract: This disclosure provides a method of determining a sequence of nucleotides for a nucleic acid template. The method can include the steps of contacting the nucleic acid template with a conformationally labeled polymerase and at least four different nucleotide species under conditions wherein the conformationally labeled polymerase catalyzes sequential addition of the nucleotide species to form a nucleic acid complement of the nucleic acid template, wherein the sequential addition of each different nucleotide species produces a conformational signal change from the conformationally labeled polymerase and wherein the rate or time duration for the conformational signal change is distinguishable for each different nucleotide species; detecting a series of changes in the signal from the conformationally labeled polymerase under the conditions; and determining the rates or time durations for the changes in the signal, thereby determining the sequence of nucleotides for the nucleic acid template.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: January 9, 2018
    Assignee: ILLUMINA, INC.
    Inventors: Molly He, Cheng-Yao Chen, Eric Kool, Mostafa Ronaghi, Michael Previte, Rigo Pantoja
  • Patent number: 9845509
    Abstract: Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, and detection probes that hybridize specifically to Legionella pneumophila 23S rRNA sequences or DNA encoding 23S rRNA. Reaction mixtures are disclosed that contain oligonucleotides for the in vitro amplification and/or detection of Legionella pneumophila 23S rRNA sequences or DNA encoding 23S rRNA. Methods are disclosed for amplifying and/or detecting the presence of L. pnuemophila in samples by using the disclosed compositions in in vitro methods that include nucleic acid amplification and/or detection of a 23S rRNA sequence or DNA encoding the 23S rRNA sequence to produce a detectable amplification product. Reaction mixtures are disclosed that contain oligonucleotides for the in vitro amplification and/or detection of Legionella pneumophila 23S rRNA sequences or DNA encoding 23S rRNA.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: December 19, 2017
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Jennifer J. Bungo, James J. Hogan, Reinhold B. Pollner, Marie K. Hudspeth, Shannon K. Kaplan, Elizabeth M. Marlowe
  • Patent number: 9834816
    Abstract: Compositions, methods, and kits for detecting one or more species of RNA molecules are disclosed. In one embodiment, a first adaptor and a second adaptor are ligated to the RNA molecule using a polypeptide comprising double-strand specific RNA ligase activity, without an intervening purification step. The ligated product is reverse transcribed, then at least some of the ribonucleosides in the reverse transcription product are removed. Primers are added and amplified products are generated. In certain embodiments, the sequence of at least part of at least one species of amplified product is determined and at least part of the corresponding RNA molecule is determined. In some embodiments, at least some of the amplified product species are detected, directly or indirectly, allowing the presence and/or quantity of the RNA molecule of interest to be determined.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 5, 2017
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventor: R. Scott Kuersten
  • Patent number: 9810609
    Abstract: Apparatus for transferring biological material onto storage media, said apparatus comprising a powered hand held device including a powered hammer arrangement, the apparatus further comprising an anvil arrangement and a storage media accepting area between the hammer and the anvil, the apparatus being operable such that in use the storage media is repeatedly compressed between the hammer and the anvil by blows from the hammer.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: November 7, 2017
    Assignee: GE Healthcare UK Limited
    Inventors: Stevan Paul Tortorella, William A. Garwood
  • Patent number: 9790250
    Abstract: The invention relates to a method and kits for isolating and/or purifying nucleic acids, in particular, short-chain nucleic acids, from a nucleic acid containing starting material, characterized by the following method steps: (a) bonding the nucleic acids to a nucleic acid bonding support material, wherein the starting material is brought into contact with the nucleic acid bonding support material in the presence of at least one chaotropic compound and preferably isopropanol, wherein the isopropanol is present in a concentration of ?25% (v/v) and ?35% (v/v), (b) optional elution of the bonded nucleic acids from the nucleic acid bonding support material. Said method is particularly suitable for the purification of foetal DNA from maternal blood.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: October 17, 2017
    Assignee: QIAGEN GmbH
    Inventors: Christoph Ritt, Martin Horlitz, Markus Sprenger-Haussels
  • Patent number: 9777314
    Abstract: Methods for capturing and characterizing low frequency nucleic acid molecules indicative of diseases such as cancer (e.g. adenomas or early stage cancers) are provided. In some aspects, a low complexity capture technique is combined with a high complexity analytical technique. In some aspects, samples may be analyzed using a digital analysis and/or a single molecule sequencing technique.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: October 3, 2017
    Assignee: Esoterix Genetic Laboratories, LLC
    Inventor: Anthony P. Shuber
  • Patent number: 9725760
    Abstract: Methods and compositions for the amplification of nucleic acids and generation of concatemers are disclosed. Amplification methods provided herein may be performed under isothermal conditions. Methods and compositions may include reagents such nucleic acid polymerases and primers.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: August 8, 2017
    Assignee: Theranos, Inc.
    Inventors: Kamila Belhocine, Josephine Lee, Pranav Patel, Aaron Richardson, Scott Tabakman
  • Patent number: 9719080
    Abstract: Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 1, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Charles P. Venditti, Randy J. Chandler
  • Patent number: 9657345
    Abstract: Provided is a dual-hybridization polynucleotide including a first complementary region that is complementary to the 3?-terminus of a target nucleic and a second complementary region that is complementary to the 5?-terminus of the target nucleic acid, a composition and kit including the polynucleotide, and a method of producing a nucleotide sequence complementary to the target nucleic acid. The first complementary region to be bound at the 3?-terminus of the target nucleic acid can be shortened and the target nucleic acid may be amplified with excellent specificity and/or sensitivity.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: May 23, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Dong-hyun Park, Sung-woo Hong, Kyung-hee Park, Myo-yong Lee
  • Patent number: 9650427
    Abstract: The invention provides methods, compositions, and kits featuring novel RIG-I like receptor activators or inhibitors for use in preventing or treating virus infection or autoimmune disease.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: May 16, 2017
    Assignee: Children's Medical Center Corporation
    Inventor: Jonathan C. Kagan
  • Patent number: 9650628
    Abstract: The present invention provides methods, compositions and kits for targeted nucleic acid sequence enrichment in a nucleic acid sample and for high efficiency nucleic acid library generation for next generation sequencing (NGS). Specifically, the methods, compositions and kits provided herein are useful for the production and capture of amplification-ready, target-specific and strand-specific regions of interest from nucleic acid samples containing complex DNA.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: May 16, 2017
    Assignee: NUGEN TECHNOLOGIES, INC.
    Inventors: Doug Amorese, Chris Armour, Nurith Kurn
  • Patent number: 9624519
    Abstract: An embodiment of a method for generating a population of amplified concatamer products is described that comprises amplifying a template nucleic acid molecule using a first nucleic acid primer immobilized on a bead substrate and a second nucleic acid primer in solution to generate a population of substantially identical copies of the template nucleic acid molecule immobilized on the bead substrate; and amplifying the population of substantially identical copies of the template nucleic acid molecule using a concatamer primer that comprises a first region complementary to an end region of the population of substantially identical copies of the template nucleic acid molecule and a second region to generate a population of immobilized concatamer products of the substantially identical copies of the template nucleic acid molecule.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: April 18, 2017
    Assignee: 454 Life Sciences Corporation
    Inventors: Brian Christopher Godwin, Priya Shanbhag, Craig Elder Mealmaker, Gianni Calogero Ferreri, Melinda Palmer, Shally Hsueh-Wen Wang
  • Patent number: 9624534
    Abstract: Compositions, methods, and kits for detecting one or more species of RNA molecules are disclosed. In one embodiment, a first adaptor and a second adaptor are ligated to the RNA molecule using a polypeptide comprising double-strand specific RNA ligase activity, without an intervening purification step. The ligated product is reverse transcribed, then at least some of the ribonucleosides in the reverse transcription product are removed. Primers are added and amplified products are generated. In certain embodiments, the sequence of at least part of at least one species of amplified product is determined and at least part of the corresponding RNA molecule is determined. In some embodiments, at least some of the amplified product species are detected, directly or indirectly, allowing the presence and/or quantity of the RNA molecule of interest to be determined.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 18, 2017
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventor: R. Scott Kuersten
  • Patent number: 9617329
    Abstract: The present disclosure provides methods for producing expression constructs comprising linking a plurality of unlinked nucleic acids, including a nucleic acid encoding a marker protein.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: April 11, 2017
    Assignee: CSL Limited
    Inventors: Con Panousis, Chao-Guang Chen
  • Patent number: 9615550
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 11, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
  • Patent number: 9616083
    Abstract: It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholesterolemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate complexes.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: April 11, 2017
    Assignee: REPLICOR INC
    Inventors: Michel Bazinet, Andrew Vaillant
  • Patent number: 9587269
    Abstract: In some embodiments, methods for obtaining sequence information from a nucleic acid template linked to a support include hybridizing a first primer to a template strand linked to a support, sequencing a portion of the nucleic acid template, thereby forming an extended first primer product that is complementary to a portion of the nucleic acid template, In some embodiments, the method further includes introducing a nick into a portion of the template strand that is hybridized to the extended first primer product, degrading a portion of the template strand from the nick using a degrading agent, where a portion of the extended first primer remains hybridized to an undegraded portion of the template strand, and sequencing at least some of the single-stranded portion of the extended first primer by synthesis.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: March 7, 2017
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Jason Myers, Zhoutao Chen, Devin Dressman, Theo Nikiforov
  • Patent number: 9541554
    Abstract: A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: January 10, 2017
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Mike Powell, Akins Doherty, Chamberlain Obialo